Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Piclidenoson - Can-Fite Biopharma

Next Previous
Drug Profile

Piclidenoson - Can-Fite Biopharma

Alternative Names: CF 101; IB-MECA; SI 615

Latest Information Update: 22 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Can-Fite BioPharma
  • Developer Can-Fite BioPharma; Fondazione Telethon
  • Class Amides; Anti-inflammatories; Antineoplastics; Antipsoriatics; Antirheumatics; Antivirals; Eye disorder therapies; Iodobenzenes; Neuroprotectants; Purine nucleosides; Ribonucleosides; Small molecules
  • Mechanism of Action Adenosine A3 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Plaque psoriasis
  • Phase II COVID 2019 infections
  • Preclinical Oculocerebrorenal syndrome; Vascular dementia
  • Discontinued Colorectal cancer; Dry eyes; Glaucoma; Ocular hypertension; Osteoarthritis; Rheumatoid arthritis; Solid tumours; Uveitis

Most Recent Events

  • 16 Dec 2025 Can-Fite BioPharma announces its intention to submit a Phase II study protocol for the rare genetic disease Lowe Syndrome to the regulatory authorities in Italy and EMA during the first quarter of 2026
  • 16 Dec 2025 Can-fite Biopharma plans a phase II trial for Oculocerebrorenal syndrome in the European Union including Italy
  • 28 Jul 2025 Preclinical trials in Vascular dementia in USA (unspecified route)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top